Company intelligence / Profile preview

Erganeo

Ownership: Private
Development stage: Other

Overview

Erganeo specializes in identifying disruptive deep tech innovations from public research institutions in France and accelerating their translation into commercial applications. It has enabled the creation or growth of several biotech startups with promising preclinical results—such as first-in-class small molecules targeting CXCR4 for autoimmune diseases with demonstrated proof-of-concept in animal models—and gene therapies for neurodegenerative disorders. Some projects have advanced toward early clinical development through its support.

Therapeutic areas: NeurologyOncologyOtherImmunologyRheumatology
Modalities: Small moleculeGene therapyExosome-based therapyMedical deviceVaccineTissue engineeringImplantable devicesBiologicExtracellular vesiclesRegenerative medicine tools
Industry: Investors

Partnerships

CNRSUniversité Paris Citéventure funds

Beyond the preview

Go deeper on Erganeo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erganeo.

Explore the full profile